You are viewing the site in preview mode
Skip to main content
|
Systemic therapy line, n (%a)
|
Treatment details
|
|---|
|
First-line (n = 86, 100 %)
|
Single-agent chemtoherapy (n = 62, 72 %)
|
|
Doxorubicin (n = 43)
|
|
Clinical trial (n = 7)
|
|
Ifosfamide (n = 4)
|
|
Paclitaxel (n = 3)
|
|
Other (n = 5)
|
|
Combination therapy (n = 24, 28 %)
|
|
Doxorubicinb and ifosfamide (n = 13)
|
|
Clinical trial (n = 7)
|
|
Other combination (n = 4)
|
|
Second-line (n = 38, 44 %)
|
Single-agent chemtoherapy (n = 35, 92 %)
|
|
Ifosfamide (n = 20)
|
|
Dacarbazine (n = 5)
|
|
Pazopanib (n = 3)
|
|
Clinical trial (n = 3)
|
|
Other (n = 4)
|
|
Combination therapy (n = 3, 8 %)
|
|
Third-line (n = 20, 23 %)
|
Single-agent chemtoherapy (n = 18, 90 %)
|
|
Pazopanib (n = 6)
|
|
Dacarbazine (n = 6)
|
|
Cyclophophamide (n = 3)
|
|
Other (n = 3)
|
|
Combination therapy (n = 2, 10 %)
|
|
Fourth-line (n = 6, 7 %)
|
Single-agent chemtoherapy (n = 6, 100 %)
|
|
Pazopanib (n = 2)
|
|
Doxorubicin (n = 1)
|
|
Ifosfamide (n = 1)
|
|
Cyclophophamide (n = 1)
|
|
Trabectedin (n = 1)
|
|
Fifth-line (n = 1, 1 %)
|
Pazopanib (n = 1)
|
-
aThe percentage refers to the proportion of patients who received the corresponding line treatment out of the total number treated with systemic therapy (n = 86)
-
bOne patient had epirubicin and ifosfamide
